Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

American Journal of Obstetrics and Gynecology

Volumn 175, Issue 6, 1996, Pages 1586-1593

  Alexander, M ^a   Salgaller, M L ^a   Celis, E ^a   Sette, A ^a   Barnes, W A ^a   Rosenberg, S A ^a   Steller, M A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cervical cancer; cytolytic T lymphocytes; Human papillomavirus; peptide epitopes; vaccine

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; ONCOPROTEIN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL SURFACE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEUKAPHERESIS; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 0030466136     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70110-2     Document Type: Article

References (25)

1. P Pisani DM Parkin J. Ferlay Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden Int J Cancer 55 1993 891 903
2. FX Bosch MM Manos N Munoz Prevalence of human papillomavirus in cervical cancer: a worldwide perspective J Natl Cancer Inst 87 1995 796 802
3. T Crook JP Morgenstern L Crawford L Banks Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ- ras EMBO J 8 1989 513 519
4. K Munger M Scheffner JM Huibregtse PM. Howley Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products Cancer Surv 12 1992 197 217
5. K Nasiell V Roger M. Nasiell Behavior of mild cervical dysplasia during long-term follow-up Obstet Gynecol 67 1986 665 669
6. M Maiman RG Fruchter E Serur JC Remy G Feuer J. Boyce Human immunodeficiency virus infection and cervical neoplasia Gynecol Oncol 38 1990 377 382
7. V Shamanin M Glover C Rausch Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients Cancer Res 54 1994 4610 4613
8. DR Madden JC Gorga JL Strominger DC. Wiley The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation Nature 353 1991 321 325
9. MC Feltkamp HL Smits MP Vierboom Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16–transformed cells Eur J Immunol 23 1993 2242 2249
10. E Schwarz UK Freese L Gissmann Structure and transcription of human papillomavirus sequences in cervical carcinoma cells Nature 314 1985 111 114
11. WM Kast RM Brandt JW Drijfhout CJ. Melief Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2 J Immunother 14 1993 115 120
12. C Yee I Krishnan-Hewlett CC Baker R Schlegel PM. Howley Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines Am J Pathol 119 1985 361 366
13. MM Pater A. Pater Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix Virology 145 1985 313 318
14. RD Salter P. Cresswell Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid EMBO J 5 1986 943 949
15. KA. Hopkins Basic microlymphocytotoxicity test ASHI laboratory manual 1990 American Society for Histocompatibility and Immunogenetics Lenexa (KS) 195 201
16. WM Kast RM Brandt J Sidney Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins J Immunol 152 1994 3904 3912
17. SL Topalian LM Muul D Solomon SA. Rosenberg Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials J Immunol Methods 102 1987 127 141
18. SA Rosenberg MT Lotze LM Muul A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 316 1987 889 897
19. Y Kawakami S Eliyahu K Sakaguchi Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2–restricted tumor infiltrating lymphocytes J Exp Med 180 1994 347 352
20. Y Kawakami S Eliyahu C Jennings Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression J Immunol 154 1995 3961 3968
21. ML Salgaller JS Weber S Koenig JR Yannelli SA. Rosenberg Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide Cancer Immunol Immunother 39 1994 105 116
22. E Celis V Tsai C Crimi Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes Proc Natl Acad Sci U S A 91 1994 2105 2109
23. ME Ressing A Sette RM Brandt Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides J Immunol 154 1995 5934 5943
24. TD. Lee Distribution of HLA antigens in North American caucasions, North American blacks and orientals J Lee The HLA system: a new approach. 1990 Springer-Verlag New York 141 178
25. NP Restifo F Esquivel Y Kawakami Identification of human cancers deficient in antigen processing J Exp Med 177 1993 265 272